MNPR Monopar Therapeutics Inc

1,738

$0.3106

$0.0194

(5.88%)

Today

Watchers	1,738
52-Wk Low	$0.2739
52-Wk High	$3.82

Market Cap	$4.91M
Volume (M)	268.00
52-Wk High	$3.82
52-Wk Low	$0.2739

Fundamentals

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsGlobe Newswire • 26 days ago

MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual...

Share to Feed

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingGlobe Newswire • about 1 month ago

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceGlobe Newswire • about 2 months ago

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobe Newswire • 3 months ago

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Therapeutics (NASDAQ:MNPR) Shares Down 1.4%Zolmax • 3 months ago

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR Get Free Report) fell 1.4% during mid-day trading on Monday . The stock traded as low as $0.63 and last traded at $0.64. 12,200 shares traded...

Monopar Therapeutics (NASDAQ:MNPR) Trading Down 5.2%Zolmax • 4 months ago

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR Get Free Report) dropped 5.2% during trading on Friday . The company traded as low as $0.66 and last traded at $0.71. Approximately 36,785 shares were traded during trading, a decline of 84% from the average daily volume of 228,586 shares. The...

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent DevelopmentsGlobe Newswire • 4 months ago

Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-...

Monopar Therapeutics GAAP EPS of -$0.16 beats by $0.03SeekingAlpha.com: All News • 4 months ago

Monopar Provides Encouraging Camsirubicin Clinical Data UpdateGlobe Newswire • 4 months ago

WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR),a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer,todayprovided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of ...

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of SingaporeGlobe Newswire • 5 months ago

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the ...